Alterations in promoter methylation status of tumor suppressor HIC1, SFRP2, and DAPK1 genes in prostate carcinomas

DNA and Cell Biology

Volumn 31, Issue 5, 2012, Pages 826-832

  Kilinc, Devran ^a   Ozdemir, Oztürk ^a,b   Ozdemir, Semra ^b   Korgali, Esat ^a   Koksal, Binnur ^a   Uslu, Atilla ^c   Gultekin, Yener E ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

^b ÇANAKKALE ONSEKIZ MART UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; SECRETED FRIZZLED RELATED PROTEIN 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CPG ISLAND; DEATH ASSOCIATED PROTEIN KINASE 1 GENE; DISEASE MARKER; DNA METHYLATION; GENE FREQUENCY; GENETIC ALGORITHM; HUMAN; HUMAN TISSUE; HYPERMETHYLATED IN CANCER 1 GENE; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; DNA; DNA METHYLATION; GENOTYPE; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84861414700     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2011.1431     Document Type: Article

References (52)

1. Awakura, Y., Nakamura, E., Ito, N., Kamoto, T., and Ogawa, O. (2008). Methylation-associated silencing of TU3A in human cancers. Int J Oncol 33, 893-899.
2. Berezovska, O.P., Glinskii, A.B., Yang, Z., Li, X.M., Hoffman, R.M., and Glinsky, G.V. (2006). Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 5, 1886-1901. (Pubitemid 44435335)
3. Boyd, V.L., and Zon, G. (2004). Bisulfite conversion of genomic DNA for methylation analysis: protocol simplification with higher recovery applicable to limited samples and increased throughput. Anal Biochem 326, 278-280. (Pubitemid 38293391)
4. Britschgi, C., Rizzi, M., Grob, T.J., Tschan, M.P., Hügli, B., Reddy, V.A., Andres, A.C., Torbett, B.E., Tobler, A., and Fey,M.F. (2006). Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer1. Oncogene 25, 2030-2039.
5. Brophy, P.D., Lang, K.M., and Dressler, G.R. (2003). The secreted frizzled related protein 2 (SFRP2) gene is a target of the Pax2 transcription factor. J Biol Chem 278, 52401-52405. (Pubitemid 38035831)
6. Carter, M.G., Johns, M.A., Zeng, X., Zhou, L., Zink, M.C., Mankowski, J.L., Donovan, D.M., and Baylin, S.B. (2000). Mice deficient in the candidate tumor suppressor gene HIC1 exhibit developmental defects of structures affected in the Miller-Dieker syndrome. Hum Mol Genet 9, 413-419. (Pubitemid 30098735)
7. Catto, J.W., Azzouzi, A.R., Rehman, I., Feeley, K.M., Cross, S.S., Amira, N., Fromont, G., Sibony, M., Cussenot, O., Meuth, M., and Hamdy, F.C. (2005). Promoter hypermethylation is associated with tumor location, stage and subsequent progression in transitional cell carcinoma. J Clin Oncol 23, 2903-2910. (Pubitemid 46224108)
8. Catto, J.W., Miah, S., Owen, H.C., Bryant, H., Myers, K., Dudziec, E., Larré, S., Milo, M., Rehman, I., Rosario, D.J., Di Martino, E., Knowles, M.A., Meuth, M., Harris, A.L., and Hamdy, F.C. (2009). Distinct microRNA alterations charactherize high-and-low-grade bladder cancer. Cancer Res 69,8472-8481.
9. Chen, W.Y., Cooper, T.K., Zahnow, C.A., Overholtzer, M., Zhao, Z., Ladanyi, M., Karp, J.E., Gokgoz, N., Wunder, J.S., Andrulis, I.L., Levine, A.J., Mankowski, J.L., and Baylin, S.B. (2004). Epigenetic and genetic loss of HIC1 function accentuates the role of p53 in tumorigenesis. Cancer Cell 6, 387-398. (Pubitemid 39361439)
10. Chen, W.Y., Zeng, X., Carter, M., Morrell, C.N., Chiu Yen R.W., Esteller, M., Watkins, D.N., Herman, J.G., Mankowski, J.L., and Baylin, S.B. (2005). Heterozygous disruption of HIC-1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet 33, 197-202. (Pubitemid 36177074)
11. Chin, L., Jason, P., and Depinto, R.A. (1998). The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem Sci 23, 291-296. (Pubitemid 28461894)
12. Clark, S.J., Statham, A., Stirzaker, C., Molloy, P.L., and Frommer,M. (2006). DNA methylation: bisulphite modification and analysis. Nature Protocols 1, 2353-2364.
13. Costello, J.F., and Plass, C. (2001). Methylation Matters. J Med Genet 38, 285-303. (Pubitemid 32433981)
14. Dahl, E., Wiesmann, F., Woenckhaus, M., Stoehr, R., Wild, P.J., Veeck, J., Knüchel, R., Klopocki, E., Sauter, G., Simon, R., Wieland, W.F., Walter, B., Denzinger, S., Hartmann, A., and Hammerschmied, C.G. (2007). Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene26, 5680-5691. (Pubitemid 47267837)
15. Dehennaut, V., and Leprince, D. (2009). Implication of HIC1 (Hypermethylated In Cancer 1) in the DNA damage response. Bull Cancer 96, 66-72.
16. Eldik, L.J.V. (2002). Structure and enzymology of a deathassociated protein kinase. Trends Pharmacol Sci 23, 302-304.
17. Esteller, M. (2000). Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer 36, 2294-2300.
18. Fleuriel, C., Touka, M., Boulay, G., Guérardel, C., Rood, B.R., and Leprince, D. (2009). HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors. Int J Biochem Cell Biol 41, 26-33.
19. Hayashi, M., Tokuchi, Y., Hashimoto. T., Hayashi, S., Nishida, K., Ishikawa, Y., Nakagawa, K., Tsuchiya, S., Okumura, S., and Tsuchiya, E. (2001). Reduced HIC1 gene expression in non-small cell lung cancer and its clinical significance. Anticancer Res 21, 535-540. (Pubitemid 32267567)
20. Hayatsu, H. (2008). Discovery of bisulfite-mediated cytosine conversion to uracil, the key reaction for DNA methylation analysis-a personal account. Proc Jpn Acad Ser B Phys Biol Sci 84, 321-330.
21. Hoffmann, M.J., Engers, R., and Florl, A.R. (2007). Expression changes in EZH2, but not in BMI-1,SIRT1,DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Ther 6, 1403-1412. (Pubitemid 351590350)
22. Huang, Z., Li, L., and Wang, J. (2007). Hypermethylation of SFRP2 as a Potential Marker for Stool-Based Detection of Colorectal Cancer and Precancerous Lesions. Dig Dis Sci 52, 2287-2291. (Pubitemid 47246528)
23. Jones, P.A., and Baylin, S.B. (2002). The fundamental role of epigenetic events in cancer. Nat Rev Genet 3, 415-428. (Pubitemid 34587077)
24. Kim, Y.K., and Kim, W.J. (2009). Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol 16, 17-22.
25. Kuo, J.C., Wang, W.J., Yao, C.C., Wu, P.R., and Chen, R.H. (2006). The tumor suppressor DAPK inhibits cell motility by blocking the integrin-mediated polarity pathway. J Cell Biol 172, 619-631.
26. Lin, Y., Hupp, T.R., and Stevens, C. (2010). Death-associated protein kinase (DAPK) and signal transduction: additional roles beyond cell death. FEBS Journal 277, 48-57.
27. Marsit, C.J., Houseman, E.A., Christensen, B.C., Eddy, K., Bueno, R., Sugarbaker, D.J., Nelson, H.H., Karagas, M.R., and Kelsey, K.T. (2006a). Examination of a CpG island methylatorphenotype and implications of methylation profiles in solid tumors. Cancer Res 66, 10621-10629. (Pubitemid 44799786)
28. Marsit, C.J., Karagas, M.R., Andrew, A., Liu, M., Danaee, H., Schned, A.R., Nelson, H.H., and Kelsey, K.T. (2005). Epigenetic inactivation of SFRP genes and TP53 Alteration Act jointly as markers of invasive bladder cancer. Cancer Res 65, 7081-7085. (Pubitemid 41161235)
29. Marsit, C.J., McClean, M.D., Furniss, C.S., and Kelsey, K.T. (2006b). Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma. Int J Caner 119, 1761-1766. (Pubitemid 44356831)
30. Mii, Y., and Taira, M. (2009). Secreted Frizzled-related proteins enhance the diffusion of Wnt ligands and expand their signaling range. Development 136, 4083-4088.
31. Mohammad, H.P., Zhang, W., Prevas, H.S., Leadem, B.R., Zhang, M., Herman, J.G., Hooker, C.M., Watkins, D.N., Karim, B., Huso, D.L., and Baylin, S.B. (2011). Loss of a single HIC1 allele accelerates polyp formation in Apc(D716) mice. Oncogene 30, 2659-2669.
32. Morton, R.A. Jr., Watkins, J.J., Bova, G.S., Wales, M.M., Baylin, S.B., and Isaacs, W.B. (1996). Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue. J Urol 156, 512-516. (Pubitemid 126445370)
33. Naqvi, A., Hoffman, T.A., DeRicco, J., Kumar, A., Kim, C.S., Jung, S.B., Yamamori, T., Kim, Y.R., Mehdi, F., Kumar, S., Rankinen, T., Ravussin, E., and Irani, K. (2010). A single-nucleotide variation in a p53-binding site affects nutrient-sensitive human SIRT1 expression. Hum Mol Genet 19, 4123-4133.
34. Nicoll, G., Crichton, D.N., McDowell, H.E., Kernohan, N., Hupp, T.R., and Thompson, A.M. (2001). Expression of the Hypermethylated in Cancer gene (HIC1) is associated with good outcome in human breast cancer. Br J Cancer 85, 1878-1882. (Pubitemid 34775324)
35. Nojima, M., Suzuki, H., Toyota, M., Watanabe, Y., Maruyama, R., Sasaki, S., Sasaki, Y., Mita, H., Nishikawa, N., Yamaguchi, K., Hirata, K., Itoh, F., Tokino, T., Mori, M., Imai, K., and Shinomura, Y. (2007). Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signalling in gastric cancer. Oncogene 26, 4699-4713. (Pubitemid 47067406)
36. Ozdemir, O., Yildiz, S., Gül, E., Koksal, B., and Yildiz, F. (2010). The combine effect of tissue specific tumor suppressor genes inactivation and point mutation in c-myc, K-ras proto-oncogenes in urinary (transitional cell) bladder carcinomas. Health 2, 850-856.
37. Paz, M.F., Fraga, M.F., Avila, S., Guo, M., Pollan, M., Herman, J.G., and Esteller, M. (2003). A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 63, 114-121.
38. Pinte, S., Guérardel, C., Deltour-Balerdi, S., Godwin, A.K. Leprince, D. (2004). Identification of a second G-C-rich promoter conserved in the human, murine and rat tumor suppressor genes HIC1. Oncogene 23, 4023-4031. (Pubitemid 38747931)
39. Rood, B.R., Zhang, H., Weitman, D.M., and Cogen, P.H. (2002). Hypermethylation of HIC1 and 17p allelic loss in medulloblastoma. Cancer Res 62, 3794-3797. (Pubitemid 34728863)
40. Schulz, W.A., and Hoffmann, M.J. (2009). Epigenetic mechanisms in the biology of prostate cancer. Semin Cancer Biol 19, 172-180.
41. Sen, M., Ozdemir, O., Turan, M., Arici, S., Yildiz, F., Koksal, B., and Goze, F. (2010). Epigenetic inactivation of tumor suppressor SFRP2 and point mutation in KRAS proto -oncogene in fistula -associated mucinous type anal adenocarcinoma: report of two cases. Intern Med 49, 1637-1640.
42. Shih, Y.L., Hsieh, C.B., Lai, H.C., Yan, M.D., Hsieh, T.Y., Chao, Y.C., and Lin, Y.W. (2007). SFRP1 suppressed hepatoma cells growth through Wnt canonical signalling pathway. Int J Cancer 121, 1028-1035.
43. Simon, J.A., and Lange, C.A. (2008). Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647, 21-29.
44. Tseng, R.C., Lee, C.C., Hsu, H.S., Tzao, C., and Wang, Y.C. (2009). Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients.Neoplasia 11, 763-770.
45. Van Leenders, G.J., Dukers, D., Hessels, D., van den Kieboom, S.W., Hulsbergen, C.A., Witjes, J.A., Otte, A.P., Meijer, C.J., and Raaphorst, F.M. (2007). Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 52, 455-463. (Pubitemid 46963432)
46. Van Rechem, C., Boulay, G., Pinte, S., Stankovic-Valentin, N., Guérardel, C., and Leprince, D. (2010). Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/ SUMOylation switch, in quiescent versus proliferating cells. Mol Cell Biol 30, 4045-4059.
47. Waha, A., Koch, A., Hartmann, W., Mack, H., Schramm, J., Sörensen, N., Berthold, F., Wiestler, O.D., Pietsch, T., and Waha, A. (2004). Analysis of HIC1 methylation and transcription in human ependymomas. Int J Cancer 110, 542-549. (Pubitemid 38658019)
48. Wales, M.M., Biel, M.A., el Deiry, W., Nelkin, B.D., Issa, J.P., Cavenee, W.K., Kuerbitz, S.J., and Baylin, S.B. (1995). p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 570-577.
49. Wolff, E.M., Liang, G., and Jones, P.A. (2005). Mechanisms of Disease: genetic and epigenetic alterations that drive bladdercancer. Nat Clin Pract Urol 2, 502-510. (Pubitemid 41594404)
50. Yegnasubramanian, S., Kowalski, J., Gonzalgo, M.L., Zahurak, M., Piantadosi, S., Walsh, P.C., Bova, G.S., De Marzo, A.M., Isaacs, W.B., and Nelson, W.G. (2004). Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64, 1975-1986. (Pubitemid 38339443)
51. Zhang, Z., Karam, J., Frenkel, E., Sagalowsky, A., and Hsieh, J.T. (2006). Epigenetic gene silencing, particularly tumor suppressor genes, has become a new area of cancer research. The application of epigenetic modifiers on the treatment of prostate and bladder cancer. Urol Oncol 24, 152-160.
52. Zhong, Y., Huang, Y., Huang, Y., Zhang, T., Ma, C., Zhang, S., Fan, W., Chen, H., Qian, J., and Lu, D. (2010). Effects of O6-methylguanine-DNA methyltransferase (MGMT) polymorphisms on cancer: a meta-analysis. Mutagenesis 25, 83-95.